Abstract
Despite evidence-based guidelines that advocate aggressive management of hyperglycemia, hypertension, and hyperlipidemia, patients with diabetes continue to suffer from high rates of cardiovascular and microvascular complications and can expect a lifespan reduction of 10 to 15 years. Our current inability to effectively and widely translate clinical evidence into usual practice represents a major barrier to reducing the burden of diabetes and its complications. Diabetes care represents a complex interaction between patients (and their families and communities), physicians (and other providers), and the health care system. Because multi-drug regimens are typically required to control hyperglycemia and the diabetes-related risk factors of hypertension and hyperlipidemia, polypharmacy is the natural consequence of providing evidence-based medical care to patients with type 2 diabetes. Within this context, we review the current evidence regarding the following three potential barriers to effective care: 1) Medication adherence in the setting of complex medical regimens, 2) Lack of medication adjustment among patients above risk factor goals, and 3) Limitations of currently organized care systems to manage complex chronic diseases such as diabetes. We also describe recent results of controlled trials of population-level, informatics-based interventions to improve diabetes care.
Keywords: Diabetes, Medication adherence, Clinical inertia, Population management, Evidence-based care, Clinical practice
Current Diabetes Reviews
Title: Overcoming Barriers to Evidence-Based Diabetes Care
Volume: 2 Issue: 2
Author(s): Richard W. Grant and James B. Meigs
Affiliation:
Keywords: Diabetes, Medication adherence, Clinical inertia, Population management, Evidence-based care, Clinical practice
Abstract: Despite evidence-based guidelines that advocate aggressive management of hyperglycemia, hypertension, and hyperlipidemia, patients with diabetes continue to suffer from high rates of cardiovascular and microvascular complications and can expect a lifespan reduction of 10 to 15 years. Our current inability to effectively and widely translate clinical evidence into usual practice represents a major barrier to reducing the burden of diabetes and its complications. Diabetes care represents a complex interaction between patients (and their families and communities), physicians (and other providers), and the health care system. Because multi-drug regimens are typically required to control hyperglycemia and the diabetes-related risk factors of hypertension and hyperlipidemia, polypharmacy is the natural consequence of providing evidence-based medical care to patients with type 2 diabetes. Within this context, we review the current evidence regarding the following three potential barriers to effective care: 1) Medication adherence in the setting of complex medical regimens, 2) Lack of medication adjustment among patients above risk factor goals, and 3) Limitations of currently organized care systems to manage complex chronic diseases such as diabetes. We also describe recent results of controlled trials of population-level, informatics-based interventions to improve diabetes care.
Export Options
About this article
Cite this article as:
Grant W. Richard and Meigs B. James, Overcoming Barriers to Evidence-Based Diabetes Care, Current Diabetes Reviews 2006; 2 (2) . https://dx.doi.org/10.2174/157339906776818604
DOI https://dx.doi.org/10.2174/157339906776818604 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bioactive Small Molecules: Promising Novel Therapies in Cardiovascular Diseases – PART I
Current Topics in Medicinal Chemistry Exogenous Factors from Venomous and Hematophagous Animals in Drugs and Diagnostic Developments for Cardiovascular and Neurovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Medicinal Agents and Metabolic Syndrome
Current Medicinal Chemistry Pericyte: Potential Target for Hemorrhagic Stroke Prevention and Treatment
Current Drug Delivery Treatment Strategies Against Diabetic Foot Ulcer: Success so Far and the Road Ahead
Current Diabetes Reviews Calcium Pattern Assessment in Patients with Severe Aortic Stenosis Via the Chou’s 5-Steps Rule
Current Pharmaceutical Design Indoles - Gut Bacteria Metabolites of Tryptophan with Pharmacotherapeutic Potential
Current Drug Metabolism Emerging Roles for Connexins in Hypertension
Current Hypertension Reviews Small-Molecules Targeting Kinases Involved in Pulmonary Hypertension: a Patent Review (2010-2015)
Current Medicinal Chemistry Aldosteronism in Heart Failure: A Proinflammatory / Fibrogenic Cardiac Phenotype. Search for Biomarkers and Potential Drug Targets
Current Drug Targets SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature
Current Pharmaceutical Design Nitroso-Redox Balance and Modulation of Basal Myocardial Function: An Update from the Italian Society of Cardiovascular Research (SIRC)
Current Drug Targets Nutrigenomics and Its Approaches for Control of Chronic Diseases
Current Biotechnology Micronutrient Intake in the Etiology, Prevention and Treatment of Osteosarcopenic Obesity
Current Aging Science Chemical Inhibition of Matrix Metalloproteinases for Periodontal Treatment
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) New Insights in Congenital Diaphragmatic Hernia
Current Respiratory Medicine Reviews Influences of Maternal Nutritional Status on Vascular Function in the Offspring
Current Drug Targets Editorial [Hot Topic: Appetite Regulation: Future Directions in Obesity Treatment (Guest Editor: Jason C.G. Halford)]
Current Drug Targets The Characteristics, Functions and Inhibitors of Three Aminopeptidases Belonging to the M1 Family
Current Protein & Peptide Science Pharmacogenetics in Methadone Therapy
Current Pharmacogenomics and Personalized Medicine